Divan A. Burger
Bloemfontein, FS, South Africa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Addressing outliers in mixed-effects logistic regression: a more robust modeling approach.
Journal: Journal of applied statistics
Published: April 06, 2026
Robust median regression for count data with general lower truncation using a contaminated discrete Weibull model.
Journal: The international journal of biostatistics
Published: June 10, 2025
Joint quantile regression of longitudinal continuous proportions and time-to-event data: Application in medication adherence and persistence.
Journal: Statistical methods in medical research
Published: December 13, 2024
Correction: Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies.
Journal: The AAPS journal
Published: May 06, 2024
Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies.
Journal: The AAPS journal
Published: October 23, 2023
A robust method for the assessment of average bioequivalence in the presence of outliers and skewness.
Journal: Pharmaceutical research
Published: June 27, 2021
Nonlinear mixed-effects modeling of longitudinal count data: Bayesian inference about median counts based on the marginal zero-inflated discrete Weibull distribution.
Journal: Statistics in medicine
Published: February 11, 2021
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
Journal: Antimicrobial agents and chemotherapy
Published: May 06, 2020
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: October 06, 2019
A robust Bayesian mixed effects approach for zero inflated and highly skewed longitudinal count data emanating from the zero inflated discrete Weibull distribution.
Journal: Statistics in medicine
Published: August 06, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Journal: The Lancet. Respiratory medicine
Published: December 11, 2018
Last Updated: 09/26/2026